Literature DB >> 31468130

Necessity of differentiating small (< 10 mm) and large (≥ 10 mm) PI-RADS 4.

Sung Yoon Park1, Byung Kwan Park2.   

Abstract

PURPOSE: Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) provides reasonable performance in detecting significant cancers. Still, it is unclear about whether all PI-RADS 4 lesions show the same cancer detection rate (CDR) regardless of tumor size. The aim was to compare the CDRs of small (< 10 mm) and large (≥ 10 mm) PI-RADS 4.
METHODS: After magnetic resonance imaging (MRI) was performed in 684 men, a radiologist interpreted the MR images and detected 281 index lesions categorized as PI-RADS 4 in 281 men. PI-RADS 4 lesions were divided into small and large groups on size of 10 mm. Overall and significant CDRs were compared between the groups. A significant cancer was defined as one with Gleason score (GS) ≥ 7 or tumor volume ≥ 0.5 ml. Tumor volumes were roughly calculated as πr34/3 (π = 3.14 and r = a half of tumor size) and were compared between the groups. Standard reference was a biopsy examination. Fisher's exact and Mann-Whitney tests were used for statistical analysis.
RESULTS: The overall CDRs of small and large groups were 39.0% (53/136) and 59.3% (86/145), respectively, (p = 0.0008). The median tumor volumes of cancer-proven small and large groups were 0.18 ml (0.01-0.38 ml) and 0.70 ml (0.52-1.44 ml), respectively (p < 0.0001). Using GS or tumor volume, the significant CDRs of these groups were 26.5% (36/136) and 59.3% (86/145), respectively (p < 0.0001), and using GS alone, 26.5% (36/136) and 39.3% (57/145), respectively (p = 0.0232).
CONCLUSIONS: PI-RADS 4 lesions should be sub-divided on size of 10 mm because of different significant CDRs.

Entities:  

Keywords:  Biopsy; Magnetic resonance imaging; Prostate Imaging Reporting and Data System; Prostate adenocarcinoma; Transrectal ultrasound

Mesh:

Year:  2019        PMID: 31468130     DOI: 10.1007/s00345-019-02924-2

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  1 in total

1.  Validation of revised Epstein's criteria for insignificant prostate cancer prediction in a Greek subpopulation.

Authors:  Κ Chondros; Ν Karpathakis; Ι Heretis; Ε Mavromanolakis; N Chondros; F Sofras; C Mamoulakis
Journal:  Hippokratia       Date:  2015 Jan-Mar       Impact factor: 0.471

  1 in total
  3 in total

1.  Comparison of biopsy strategies for prostate biopsy according to lesion size and PSA density in MRI-directed biopsy pathway.

Authors:  Mi Yeon Park; Kye Jin Park; Bumjin Lim; Mi-Hyun Kim; In Gab Jeong; Jeong Kon Kim
Journal:  Abdom Radiol (NY)       Date:  2020-07-31

2.  Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies.

Authors:  Daniël F Osses; Christian Arsov; Lars Schimmöller; Ivo G Schoots; Geert J L H van Leenders; Irene Esposito; Sebastiaan Remmers; Peter Albers; Monique J Roobol
Journal:  J Pers Med       Date:  2020-12-10

3.  New TRUS Techniques and Imaging Features of PI-RADS 4 or 5: Influence on Tumor Targeting.

Authors:  Amy Inji Chang; Byung Kwan Park
Journal:  Front Oncol       Date:  2021-06-09       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.